Zobrazeno 1 - 10 of 22 pro vyhledávání: '"John R Macdougall"'
1
Akademický článek
Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model.
Autor: Christopher K McCann, Whitfield B Growdon, Kashmira Kulkarni-Datar, Michael D Curley, Anne M Friel, Jennifer L Proctor, Hana Sheikh, Igor Deyneko, Jeanne A Ferguson, Vinod Vathipadiekal, Michael J Birrer, Darrell R Borger, Gayatry Mohapatra, Lawrence R Zukerberg, Rosemary Foster, John R Macdougall, Bo R Rueda
Publikováno v: PLoS ONE, Vol 6, Iss 11, p e28077 (2011)
Recent evidence links aberrant activation of Hedgehog (Hh) signaling with the pathogenesis of several cancers including medulloblastoma, basal cell, small cell lung, pancreatic, prostate and ovarian. This investigation was designed to determine if in
Externí odkaz: https://doaj.org/article/4e6a983d320640afaf3099882befd611
Zobrazit plný text záznamu
4
Abstract 2249: Development and validation of a pharmacodynamic (PD) assay for TOS-358, the first covalent inhibitor of PI3Kα in clinical development
Autor: John R. MacDougall, Raymond Mak, John Bradley, Allison Simpson, Claire May, Lan Wei, Kendra Ouellette, Marty Olbrot, Jimmy Blair, Neil Dhawan, Wei Chen
Publikováno v: Cancer Research. 83:2249-2249
TOS-358 is a first-in-class covalent inhibitor of PI3Kα and is currently in clinical development in a variety of solid malignancies. We have developed a fit-for-purpose pharmacodynamic assay to evaluate the target occupancy of TOS-358 in in vitro an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a4a456949391642472ad772103280841
https://doi.org/10.1158/1538-7445.am2023-2249
Zobrazit plný text záznamu
5
Abstract 4946: TOS-358, a first-in-class covalent PI3Kα inhibitor, demonstrates superior efficacy and does not induce significant hyperglycemia at efficacious doses in multiple animal models
Autor: John R. MacDougall, John Bradley, Raymond Mak, Neil Dhawan, Wei Chen
Publikováno v: Cancer Research. 83:4946-4946
PI3Kα is frequently mutated in a variety of cancer types, and the PI3K-AKT signaling axis also plays a role in insulin signaling and glucose homeostasis. TOS-358 is a highly selective first-in-class covalent inhibitor of PI3Kα and is currently in c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ae7d6f1095d79de00e863bdde35d289a
https://doi.org/10.1158/1538-7445.am2023-4946
Zobrazit plný text záznamu
6
Abstract 4945: Inhibition of wild-type PI3Kα signaling is required for durable efficacy in PI3Kα mutant cancer cells due to robust re-activation of wild-type PI3Kα signaling
Autor: John R. MacDougall, Mengqi Zhong, Hanne Merritt, Joselyn S. Del Cid, John Bradley, Raymond Mak, Neil Dhawan, Wei Chen
Publikováno v: Cancer Research. 83:4945-4945
PI3Kα is the most mutated oncogene with a high mutation rate in breast, lung, colorectal, gastric, bladder, and other tumor types. However, current inhibitors have had little efficacy in the clinic due to their inability to achieve maximal PI3Kα ta
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b8b74db29ecbdca38ad3648e072349a
https://doi.org/10.1158/1538-7445.am2023-4945
Zobrazit plný text záznamu
7
Targets of extinction: identification of genes whose expression is repressed as a consequence of somatic fusion between cells representing basal and luminal mammary epithelial phenotypes
Autor: Lynn M. Matrisian, John R. MacDougall
Publikováno v: Journal of Cell Science. 113:409-423
The use of somatic cell hybrids has led to an increased understanding of the ‘negative’ regulation of cellular phenotype. Using somatic cell hybrids constructed between human breast cells that represent differing stages of malignancy but also dis
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df744693faeacf96b5632178e1dc2a96
https://doi.org/10.1242/jcs.113.3.409
Zobrazit plný text záznamu
9
Demonstration of a splenic cytotoxic effector cell in mice of genotype SCID/SCID.BG/BG
Autor: B.Anne Croy, Christine Chapeau, David A. Clark, John R. MacDougall
Publikováno v: Cellular Immunology. 130:106-117
Splenocytes from mice of genotype scid/scid, bg/bg were tested in vitro to characterize the nature of the immunological deficit in these doubly mutant animals. The cells were unresponsive to the mitogens LPS and Con A and to alloantigens, as predicte
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::627e736839c3735403c2f0e64740b65e
https://doi.org/10.1016/0008-8749(90)90165-n
Zobrazit plný text záznamu
10
CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma
Autor: Craig Hackett, John R. Macdougall, Michael A. Gallo, Kam Fai Tse, Gadi Gazit-Bornstein, William J. LaRochelle, Suresh Shenoy, Luca Rastelli, Damon L. Meyer, Ferenc L. Boldog, Peter D. Senter, Nikolai V. Khramtsov, Melanie L Shadish, John L. Herrmann, Bing Kuang, Denise A. McCabe, Michael Jeffers, Vincent A. Pollack, Henri Lichenstein
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 12(4)
PURPOSE: Advanced melanoma is a highly drug-refractory neoplasm representing a significant unmet medical need. We sought to identify melanoma-associated cell surface molecules and to develop as well as preclinically test immunotherapeutic reagents de
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::321c78b7582b98c5d65ad69d17fc8d0b
https://pubmed.ncbi.nlm.nih.gov/16489096
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje